All studies are led by either a Fred Hutch or University of Washington investigator. Studies may be based on science completed by biotechnology or pharmaceutical companies. Study sponsors cover all clinical trial costs and under no circumstances will a participant’s insurance be charged for any service. The CCRC is not a hospital or clinic and will only have participation from volunteers that fit the study criteria and fully consent to participation.
Interested in volunteering for one of our studies? Contact us to see if you qualify.
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult Patients With SARS-CoV-2 Infection
The REGN 2067 study is testing an infusion of REGN-COV2, a combination of two antibodies against SARS-CoV-2, the virus that causes COVID-19, to see whether they can: (1) decrease the amount of virus in the body; (2) decrease the length of time the virus is in the body; and (3) decrease the length and severity of COVID-19 illness. The antibodies in this study cannot give you SARS-CoV-2.
Other protocol-defined Inclusion/Exclusion criteria may apply.
Step 1: Visit ClinicalTrials.gov, identifier NCT04425629, to determine if this study is right for you.
Step 2: If you are interested in volunteering, complete our online survey or contact us by phone or email.